Algert Global’s Accelerate Diagnostics AXDX Stock Holding History

Algert Global’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,958	Closed	-$246K	–	426
2021 Q1	$246K	Buy	2,958 +1,872	+172%	+$190K	0.08%	341
2020 Q4	$82K	Buy	+1,086	New	+$97.2K	0.02%	385

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Algert Global's AXDX Position: Q2 2021 in Review

Algert Global sold out of Accelerate Diagnostics (AXDX) in Q2 2021, closing a stake of 2,958 shares — an estimated $246K sold.

Algert Global first reported a position in AXDX in Q4 2020 and held it in 2 quarters. The position peaked at $246K in Q1 2021. 95 funds tracked by Wall St. Rank hold AXDX as of Q2 2021.

Algert Global reported no remaining Accelerate Diagnostics position as of Q2 2021 after selling out during the quarter.
Algert Global sold 2,958 Accelerate Diagnostics shares in Q2 2021, an estimated $246K.
Algert Global first reported a position in Accelerate Diagnostics in Q4 2020 and held it in 2 quarters.
Algert Global's Accelerate Diagnostics position peaked at $246K in Q1 2021.
95 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2021.

Based on Algert Global's 13F filing for Q2 2021, filed 13 Aug 2021.